SMi Group's 22nd annual Superbugs and Superdrugs 2020 conference returns to London In March

1. www.superbugssuperdrugs.com
Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711
ACADEMIC & GROUP DISCOUNTS AVAILABLE
PLUS TWO INTERACTIVE HALF-DAY POST-CONFERENCE WORKSHOPS
Wednesday 1st April 2019, Holiday Inn Kensington Forum, London, UK
@SMIPHARM
#smibugs
HIGHLIGHTS IN 2020:
• Discuss the new classes of non-antibiotic antibacterial proteins:
Colicins and Colicin-like Bacteriocins from Nomad Bioscience
• Gain valuable insight towards fighting severe and resistant
infections through neutralising bacterial virulence effectors from
Combioxin
• Examine a UK project looking at novel value assessment and
reimbursement for novel antimicrobials from NICE/Manchester
University NHS Foundation Trust
• Explore direct lytic agents (DLAs) and their potential as a
successful disruptive anti-infective technology with Contrafect
• Evaluate the utility of machine learning and AI in antibiotic drug
discovery with Oxford Drug Design
CHAIRS FOR 2020:
Cara Cassino, Chief Medical Officer,
Contrafect
Michael Dawson, Director, Mike Dawson Antimicrobial
Research Consultancy
SPEAKERS FOR 2020:
• Yuri Gleba, Professor, Founder, Nomad Bioscience
• Mark Albrecht, Branch Chief, Antibacterials program,
BARDA/HHS
• Paul Finn, CEO, Oxford Drug Design
• Cara Cassino, Chief Medical Officer, Contrafect
• Martin Everett, CSO, Antabio
• Samareh Lajaunias, Director, Combioxin SA
• Francois Moreau, Scientific Director, Mutabilis
• Emma Leire, Microbiology Lead, Centauri Therapeutics
• Lorenzo Corsini, Co-Founder/CEO/R&D, Phagomed
• Stephen Barat, VP, Preclinical Research and Early
Development, Scynexis
• Colm Leonard, Consultant Clinical Adviser/Consultant
Thoracic Physician/Honorary Professor, NICE & Manchester
University NHS Foundation Trust
A: Development of non-traditional agents
and alternatives to antibiotics
8.30 – 12.30
Workshop Leaders:
Peter Warn, Senior Vice President Anti-infective Discovery, Evotec (UK) Ltd
Antonio Felici, VP, Anti-Infectives, Evotec
B: Anti-microbial resistance
and pathogenic fungi
1.30 – 5.30
Workshop Leader:
Stephen Barat, VP, Preclinical Research and Early Development, Scynexis
SMi Presents The 22nd Annual Conference on…
A focus on non-traditional approaches
in the fight against antimicrobial resistance
HOLIDAY INN KENSINGTON FORUM, LONDON, UK
CONFERENCE:
30TH - 31ST MARCH
WORKSHOPS: 1ST APRIL
MAR
2020
Superbugs &
Superdrugs
BOOK BY 29TH NOVEMBER AND SAVE £400
BOOK BY 13TH DECEMBER AND SAVE £200
BOOK BY 31ST JANUARY AND SAVE £100
Sponsored by

2. Superbugs & Superdrugs
Day One | Monday 30th March 2020 www.superbugssuperdrugs.com
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
Cara Cassino, Chief Medical Officer, Contrafect
NOVEL ANTIMICROBIAL APPROACHES PART I
OPENING ADDRESS
9.10 Exploring new classes of non-antibiotic antibacterial proteins:
Colicins and Colicin-like Bacteriocins
• Origins of non-antibiotic antibacterial proteins - a brief
history
• A brief summary of the efficacy and potency of bacteriocins
• Methods and approach to bacteriocin expression - plant
hosts
• Key commercialisation aspects, challenges and product
candidates
Yuri Gleba, Professor, Founder, Nomad Bioscience
9.50 Neutralising bacterial virulence effectors: a new paradigm in
fighting severe and resistant infections
• Neutralising virulence effectors
• CAL02: agent chemistry and activity
• Showcasing the results of CAL02 randomised, double-blind,
multicentre, placebo-controlled trial
• Exploring the current regulatory landscape around
neutralisation of virulence factors and beyond
Samareh Lajaunias, Director, Combioxin SA
10.30 Morning Coffee
11.00 Exploring Direct Lytic Agents (DLAs) and their potential as a
successful disruptive anti-infective technology
• Analysing the characteristics and benefits of DLAs against
drug-resistant pathogens
• A look at the broad-based Gram-negative discovery
program that optimises and develops DLA targets
• Explore the Exebacase performance as the only lysin to
enter human clinical trials in the US entering phase 3
• Gain insight into the progress of the pipeline: GN Lysins and
Amurins
• Evaluating the future outlook of DLA therapeutics
Cara Cassino, Chief Medical Officer, Contrafec
DRUG DISCOVERY, DEVELOPMENT AND SUPPORT PART I
11.40 Boosting the antibiotic pipeline through the expansion of
portfolio partnerships
• An outline of the current and prospective antibiotic R&D
partnerships
• Hear about BARDA’s contribution to combat antibiotic
resistant infections in the US
• Gain insight into biopharmaceutical incubators that
facilitate meeting objectives
• Establishing a biopharmaceutical incubator to meet
short- and long-term goals
• Explore BARDA funding opportunities
Mark Albrecht, Branch Chief, Antibacterials Program,
BARDA/HHS
12.20 Networking Lunch
1.20 Candida auris: rise of a superbug
• Background, epidemiology and global spread
• Why Candida auris presents a significant cause for concern
• The concern for AMR and the potential utility of new
antifungals such as Ibrexafungerp
Stephen Barat, VP, Research & Early
Development, Scynexis
BOOSTING IMMUNITY PART I
2.00 Immunomodulatory Therapies
• Extracellular Bacterial GAPDH
• Common Virulence Mechanism
• Restore Immune system ability to control infection
Pedro Madureira, Co-Founder, CSO, Immunethep
2.40 Afternoon Tea
PANEL DISCUSSION
3.10 The development of non-traditional therapies in ID:
known and unknown hurdles
• What are non-traditional therapies?
• Could efficacy assessments (non-clinical and clinical)
used for antibiotics apply to non-traditional agents?
• Are there alternatives to antibiotics or to be administered
in combination with antibiotics?
• What are the regulatory guidelines for the development
of non-traditional therapies?
• What is the place of non-traditional therapies in terms
of financial support and regulatory designations?
• How do non-traditional therapies address the resistance
threat?
Moderator: Toni Perez, Chief Medical Officer, Senior Subject
Matter Expert, Combioxin
4.10 Chair’s Closing Remarks and Close of Day One
Register online at www.superbugssuperdrugs.com
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy.
Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion
specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company committed to positively impacting the lives
of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-
infective therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and
developing more than 30 innovative medicines over a broad range of therapeutic areas. The Company’s
lead product candidate, SCY-078, is a novel IV/oral antifungal agent in Phase 2 clinical and preclinical
development for the treatment of several serious and life-threatening invasive fungal infections caused by
Candida and Aspergillus species. For more information, visit www.scynexis.com
Sponsored by

3. Superbugs & Superdrugs
www.superbugssuperdrugs.com Day Two | Tuesday 31st March 2020
Supported by
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
MARKETING PARTNERSHIP OPPORTUNITIES
SMi Group is offering companies the opportunity to partner on our dedicated events in order to help raise your company
profile, add value, create awareness of your products/services to our key audience within the pharmaceutical industry.
Interested in partnering? Contact Simi Sapal, Marketing Manager on +44(0)207 827 6162 or email: ssapal@smi-online.co.uk
Official Media Partners
8.30 Registration & Coffee
9.00 Chair’s Opening Remarks
Michael Dawson, Director, Mike Dawson Antimicrobial
Research Consultancy
DRUG DISCOVERY, DEVELOPMENT AND SUPPORT PART II
OPENING ADDRESS
9.10 Update on the UK project looking at novel value assessment
and reimbursement for novel antimicrobials
• Background to UK project
• Components of UK project
• Progress to date and global context
Colm Leonard, Consultant Clinical Adviser/Consultant
Thoracic Physician/Honorary Professor of Medicine,
NICE & Machester University NHS Foundation Trust
9.50 Evaluating the utility of machine learning and AI in antibiotic
drug discovery
• Explore the applicability of machine learning and AI in
accelerating antibiotic drug discovery and development
• The technology behind the machine: proprietary 3D
ElectroShape technology and the Scopius compound
database
• Case study: Aminoacyl tRNA (aaRS) Synthetase Inhibitors
• See the opportunities and challenges that face regulator
and clinician acceptance
Paul Finn, CEO, Oxford Drug Design
10.30 Morning Coffee
NOVEL ANTIMICROBIAL APPROACHES PART II
11.00 Discovery and progress of Metallo-ß-Lactamase inhibitor
(MBLi) as a potent agent against NDM-carbapanem
resistant CRE
• Worldwide CRE prevalence summary
• Discovery of a novel MBL-inhibitor: ANT431 and reinstating
susceptibility
• Progress of the MBLi programme towards a preclinical
candidate: ANT2681
• The future of antibiotic adjuvants and combination therapies
Martin Everett, CSO, Antabio
11.40 Discovery of Dabocins, a novel class of non-ß-lactam
PBP inhibitors
• EBL-1463 is a DBO-based covalent inhibitor of Penicillin-
Binding Proteins 1a, 2, 3
• It is stable to class A, B, C, D ß-lactamases, direct-acting and
bactericidal against Enterobacterales
• Overview of MIC profiles and in vivo efficacy against highly
resistant MBL-producing CRE
• Early PK/PD and human dose prediction
Francois Moreau, Scientific Director, Mutabilis
12.20 Networking Lunch
1.20 Highly targeted protein antibiotics for the prevention and
treatment of bacterial infections
• Protein antibiotics that show good in vivo efficacy against
major Gram-negative pathogens have been identified
• Show extensive distribution into different organs when
administered intravenously
• Selective targeting of pathogenic species can be achieved
in the complex environment of the intestinal microbiota
Daniel Walker, Professor of Bacteriology, University of Glasgow
2.00 Precision biofilm disruption and vaginome editing with
phage-based technologies
• PhagoMed is an Austrian pre-clinical biotech company
focused on developing treatments against persistent,
biofilm-associated infections. We will present two of our key
assets
• PM-398: PhagoMed’s cocktail of natural, propagating
S. aureus phages could transform the standard of care in
implant associated infections
• PM-477: PhagoMed’s recombinant, Gardnerella-specific
endolysin precisely edits the vaginal microbiome and is
being developed for the treatment of bacterial vaginosis
Lorenzo Corsini, Co-Founder/CEO/R&D, Phagomed
2.40 Afternoon Tea
3.10 Inhibition of bacterial cell-wall biosynthesis by carbohydrate
scaffolds targeting the glycosyltransferase activity of
penicillin-binding proteins
• Penicillin binding proteins (PBPs) as excellent targets for
antibacterials as exemplified by the mode of action of
beta-lactams
• Class A PBPs are responsible for the polymerisation of the
peptidoglycan precursor, Lipid II into a glycan polymer
required for subsequent transpeptidation crosslinking
reactions by all PBPs
• Development of a series of sugar base inhibitors of this
process with promising in-vitro in-vivo properties of this Class
A PBP polymerisation process
• Exploring the mode of action providing a novel perspective
on targeting bacterial cell wall biosynthesis
David Roper, Professor of Biochemistry and Structural Biology,
University of Warwick
BOOSTING IMMUNITY PART II
4.00 Novel Immunotherapeutics to target Gram-negative bacterial
infections
• Natural antibodies and the discovery of alpha-Gal
• Alphamer platform and how to harness the power of the
immune system
• ABX01 mechanism of action in vitro and in vivo
• Translation of immune-recruiting agents in preclinical PK/PD
Emma Leire, Microbiology Lead, Centauri Therapeutics
4.40 Chair’s Closing Remarks and Close of Day Two

4. HALF-DAY POST-CONFERENCE WORKSHOP A
Wednesday 1st April 2020
8.30 – 12.30
Holiday Inn Kensington Forum, London, UK
Development of non-traditional agents
and alternatives to antibiotics
Workshop Leaders: Peter Warn, Senior Vice President
Anti-infective Discovery, Evotec (UK) Ltd
Antonio Felici, VP, Anti-Infectives, Evotec
Overview of Workshop:
In the brief 80 years since their first discovery, antibiotics have
been central in the advancement of modern medicine and
both to treat infections and as prophylaxis in numerous surgical
and medical procedures. During the 1950s through to 1970s it
appeared that the discovery of new small molecule antibiotics
was endless and that we were winning the battle against
infections. Unfortunately antibiotics are unique in medicine, in
that their initial high efficacy degrades over tome as microbes
develop resistance. Over the last two decades we have
watched the perfect storm of the pipeline drying up and the
acceleration of the development of resistance. To combat
this we require new tools to address bacterial infection. In this
workshop, we will discuss the in vitro and in vivo developments
of non-traditional antibacterial agents (products other than
classic antibacterial agents) that target bacteria or any
approaches that target the host. We will focus on the range of
approaches that can be used when burden and survival are
not appropriate endpoints and PKPD relationships are less clear.
Why you should attend:
• Understand the limitations of our current approaches in
developing antimicrobial agents
• Explore alternative approaches to developing antibiotics
when traditional methods are inappropriate
• Gain Insight into how to predict suitable dosing regimens for
non-traditional agents
• Discover how alternative approaches can be harnessed to
our advantage in the battle against infections
Programme:
8.30 Registration and Coffee
9.00 Opening Remarks and Introductions
9.10 Session 1: Portfolio of alternative approaches
• Brief review of at least 19 approaches that the
Academics and industry have produced
• Brief review of non-traditional and alternative
agents in the pipeline
• Q&A
9.50 Session 2: Development of agents that kill the
microbes
• Combination treatment
• Bacteriophages in all their flavours
• Phage lysins
• Antimicrobial peptides
• Q&A
10.20 Morning Coffee
10.50 Session 3: Development of agents that don’t (or might
not) kill the microbe
• Agents active against the biofilm or quorum sensing
• Host defence peptides and innate defence
peptides
• Metal chelators, toxin sequestration or inactivation
• Q&A
11.30 Session 4: Development of agents that alter the host
• Prebiotics, probiotics and the microbiome
• Vaccines, antibodies and anti-toxins
• Immune stimulation and regulation
• Q&A
12.30 Closing Remarks and End of Workshop
About the workshop leaders:
Dr Peter Warn is SVP of Anti-Infective Discovery at Evotec and has
a leading role in internal and external anti-infective discovery
research programs. Dr Warn helped built the anti-infective
franchise at Evotec to be the largest in the sector including
acquisitions of Sanofi anti-infectives and Aptuit. Dr Warn is a
member of the SABs of multiple Pharma and Biotechs in Europe
and the US, is a member of the EU AMR Taskforce. Previously
Dr Warn was a founder, Director and CSO of Euprotec, a CRO
focussed on anti-infective discovery. Before moving to Industry,
he was a senior academic at the Univ Manchester focusing
on the pathogenesis of severe fungal disease and the PKPD of
antifungal agents and at the Univ Oxford where he researched
the pathogenesis and treatment of severe malaria in children.
Dr Warn has published almost 100 peer-review manuscripts,
and been involved in the development of over 10 marketed
antimicrobial drugs.
Dr Antonio Felici VP Anti-infectives Microbiology Discovery
and leads antimicrobial discovery at the Aptuit site in Verona.
Previously he was a Senior Project Manager at GSK have had
previous roles as Head of Microbial Biochemistry Unit, Head of In
Vitro Chemotherapy Unit. His diverse roles included developing
the strategies; activities required for the development
commercialization of a successful antimicrobial products,
management programmes in the early lead optimisation
phase (up to candidate selection). Dr Felici also managed the
experimental activities for the evaluation of the MoA of new
antibacterials. Dr Felici studied at the Universities of Liege where
is gained a PhD in enzymology applied to biologic sciences.

5. SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising
and branding packages, uniquely tailored to
complement your company’s marketing strategy.
Prime networking opportunities exist to entertain,
enhance and expand your client base within the
context of an independent discussion
specific to your industry. Should you wish to join the
increasing number of companies benefiting from
sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email:
amalick@smi-online.co.uk
HALF-DAY POST-CONFERENCE WORKSHOP B
Wednesday 1st April 2020
1.30 – 5.30
Holiday Inn Kensington Forum, London, UK
Anti-microbial resistance
and pathogenic fungi
Workshop Leader: Stephen Barat, VP, Preclinical Research and
Early Development, Scynexis
Overview of Workshop:
The subject of anti-microbial resistance is well-recognized
amongst infectious disease, with bacteria often being in the
spotlight. However, anti-microbial resistance also exists amongst
pathogenic fungi. There are numerous examples where drug
resistance in fungi has developed and expanding. Furthermore,
the emergence of multi-drug resistance strains pose substantial
health threats, making a clear need for new and novel
treatments.
Why you should attend:
• Understand how the development of resistance in
pathogenic fungi poses challenges to currently available
therapies
• Learn about the global trends in emerging resistances
amongst fungi (Candida, Aspergillus, spp and others)
• Recognize the implications drug-resistant fungi present to
healthcare settings
• Learn about the patient populations at risk for these
infections
• Recognize why new and novel anti-fungal agents are
medically necessary
Programme:
1.30 Registration & Coffee
2.00 Opening remarks and introductions
2.10 Session 1-Anti-microbial resistance in the fungal
arena
• Development of resistance to anti-fungal drugs
• The threat posed by multi-drug resistance (MDR)
2.50 Session 2-Resistance in Candida spp
• Development of resistance in Candida spp
C. auris,: AMR and development of multi-drug
resistance (MDR)
• Resistance in C. glabrata, C. parapsilosis and others
3.30 Afternoon Tea
4.00 Session 3- Resistance in other pathogenic fungi
• Aspergillus spp and azole-resistance
• Emergence of resistance in dermatophytes
• Antifungal-resistant Mucorales
4.40 Session 4- The need for new anti-fungal drugs
• Overview of existing anti-fungals
• Challenges treating MDR strains
• The case for novel anti-fungal drugs
5.20 Closing remarks
5.30 End of workshop
About the workshop leader:
Stephen A. Barat, PhD is Vice-President of Research and Early
Development at Scynexis, a biotechnology company focused
on the development of novel treatments for serious and life-
threatening infections. Prior to joining Scynexis, Dr. Barat held
a series of positions of increasing responsibility with Allergan/
Actavis/Forest Laboratories and Schering-Plough. He has more
than 20 years of experience in global drug development and
registration, and is an internationally-recognized speaker on
drug development and CMC-related safety assessment issues.
About the organisation:
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company
committed to positively impacting the lives of patients suffering
from difficult-to-treat and often life-threatening infections by
delivering innovative anti-infective therapies. The SCYNEXIS
team has extensive experience in the life sciences industry,
discovering and developing more than 30 innovative medicines
over a broad range of therapeutic areas. The Company’s
lead product candidate, SCY-078, is a novel IV/oral antifungal
agent in Phase 2 clinical and preclinical development for the
treatment of several serious and life-threatening invasive fungal
infections caused by Candida and Aspergillus species. For more
information, visit www.scynexis.com

6. VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here.
______________________________________________________________________________________
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk
EARLY BIRD
DISCOUNT
Unique Reference Number
Our Reference LVP-312
VAT
SUPERBUGS & SUPERDRUGS 2020
Conference: Monday 30th & Tuesday 31st March 2020, Holiday Inn Kensington Forum, London, UK
Workshops: Wednesday 1st April 2020, London, UK
4 WAYS TO REGISTER
www.superbugssuperdrugs.com
□ Book by 31st October to receive £400 off the conference price
□ Book by 30th November to receive £200 off the conference price
□ Book by 13th December to receive £100 off the conference price
DOCUMENTATION
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-312 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
PAYMENT
CONFERENCE PRICES GROUP DISCOUNTS AVAILABLE
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about our
events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we
have to cancel the event for any reason, then we will make a full refund immediately, but disclaim
any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policy please go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://www.smi-online.co.uk/opt-out
Terms and Conditions of Booking
DELEGATE DETAILS
VENUE Holiday Inn Kensington Forum, London, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
POST your booking form to: Events Team, SMi Group Ltd,
India House, 45 Curlew Street, London, SE1 2ND, UK
I would like to attend: (Please tick as appropriate) Fee TOTAL
□ Conference & 2 Workshops £2697.00 + VAT £3236.40
□ Conference & 1 Workshop □ A □ B £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops only £1198.00 + VAT £1437.60
□ 1 Workshop only □ A □ B £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject to
distribution rights by speakers. Please note that some presentations may not be available
for download. Access information for the document portal will be sent to the e-mail
address provided during registration. Details are sent within 24 hours post conference.